Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Applied Therapeutics Inc. (APLT : NSDQ)
 
 • Company Description   
Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing drug candidates for unmet medical need. The company's product candidate consists of AT-001, for the treatment of Diabetic Cardiomyopathy; AT-007, for the treatment of Galactosemia and AT-003, for the treatment of diabetic retinopathy which are in clinical stage. Applied Therapeutics Inc. is based in New York, United States.

Number of Employees: 35

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.10 Daily Weekly Monthly
20 Day Moving Average: 10,497,605 shares
Shares Outstanding: 153.96 (millions)
Market Capitalization: $15.40 (millions)
Beta: 2.08
52 Week High: $1.50
52 Week Low: $0.09
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -56.50% -56.43%
12 Week -90.48% -90.63%
Year To Date 0.00% 0.00%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
545 5TH AVENUE SUITE 1400
-
NEW YORK,NY 10017
USA
ph: 212-220-9226
fax: -
appliedtherapeutics@argotpartners.com http://www.appliedtherapeutics.com
 
 • General Corporate Information   
Officers
Les Funtleyder - Interim Chief Executive Officer; Chief Financial O
John Johnson - Executive Chairman and Director
Constantine Chinoporos - Chief Operating Officer and Chief Business Officer
Catherine Thorpe - Interim Chief Accounting Officer
Stacy Kanter - Director

Peer Information
Applied Therapeutics Inc. (CORR.)
Applied Therapeutics Inc. (RSPI)
Applied Therapeutics Inc. (CGXP)
Applied Therapeutics Inc. (BGEN)
Applied Therapeutics Inc. (GTBP)
Applied Therapeutics Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03828A101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 04/13/26
Share - Related Items
Shares Outstanding: 153.96
Most Recent Split Date: (:1)
Beta: 2.08
Market Capitalization: $15.40 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.10 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.47 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 04/13/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 35.00%
vs. Previous Quarter: 13.33%
Sales Growth
vs. Year Ago Period: 719.67%
vs. Previous Quarter: -%
ROE
12/31/25 - -
09/30/25 - -340.84
06/30/25 - -354.24
ROA
12/31/25 - -
09/30/25 - -175.00
06/30/25 - -144.16
Current Ratio
12/31/25 - -
09/30/25 - 0.96
06/30/25 - 1.94
Quick Ratio
12/31/25 - -
09/30/25 - 0.96
06/30/25 - 1.94
Operating Margin
12/31/25 - -
09/30/25 - -
06/30/25 - -
Net Margin
12/31/25 - -
09/30/25 - -
06/30/25 - -
Pre-Tax Margin
12/31/25 - -
09/30/25 - -1,813.80
06/30/25 - -55,523.77
Book Value
12/31/25 - -
09/30/25 - 0.00
06/30/25 - 0.12
Inventory Turnover
12/31/25 - -
09/30/25 - -
06/30/25 - -
Debt-to-Equity
12/31/25 - -
09/30/25 - -
06/30/25 - 0.00
Debt-to-Capital
12/31/25 - -
09/30/25 - -
06/30/25 - 0.00
 

Powered by Zacks Investment Research ©